{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.528","value":"163.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"}],"units":"Participants"}],"title":"End of infusion: C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.622","value":"269.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"title":"End of infusion: C1D15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.921","value":"299.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"}],"units":"Participants"}],"title":"End of infusion: C2D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.555","value":"279.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"}],"units":"Participants"}],"title":"End of infusion: C4D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"}],"units":"Participants"}],"description":"CEOI was defined as the plasma concentration at end of infusion.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG000","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Analysis was performed on PK population which included participants who received at least 1 dose of Isatuximab, with data for at least 1 PK parameter available. Here, 'Number analyzed' = participants with available data for each specified category. Data for this outcome measure (OM) was not planned to be collected and analyzed for Pd arm.","reportingStatus":"POSTED","timeFrame":"End of infusion on Cycle(C)1 Day(D)1 and Cycle1 Day 15; Cycle 2 Day 1; and Cycle 4 Day 1","title":"Pharmacokinetics (PK) Parameter: Plasma Concentration of Isatuximab at End of Infusion (CEOI)","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (mcg/mL)"}